Fatigue in inflammatory rheumatic diseases frequently persists after clinically visible inflammation has improved, a mismatch termed the 'fatigue remission gap'.
This narrative review of evidence through July 2026 finds that fatigue in RA, SLE, and SjD is more strongly associated with pain, sleep disturbance, mood, and central pain sensitivity than with conventional inflammatory measures. In a 2026 RA cohort of 253 patients, 80% reported fatigue and 10% had severe fatigue, with fatigue present even in remission. The authors propose a treatable-traits framework to address this gap rather than escalating immunosuppression.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Fatigue in inflammatory rheumatic diseases frequently persists after clinically visible inflammation has improved, a mismatch termed the 'fatigue remission gap'. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Fatigue in inflammatory rheumatic diseases frequently persists after clinically visible inflammation has improved, a mismatch termed the 'fatigue remission gap'.
This conclusion is most relevant to: Patients with inflammatory rheumatic diseases (RA, SLE, Sjögren's disease), including a 253-patient RA cohort and an international survey of 1,155 people with SjD..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework. (Rheumatology international, 2026) —
How It Works
The proposed biological pathway:
- ▸Inflammation improves with treatment, but fatigue persists in many patients
- ▸Fatigue is more strongly linked to non-inflammatory factors (pain, sleep, mood, central sensitization)
- ▸Central pain sensitivity improvement tracks fatigue improvement in longitudinal RA data
- ▸Result: Fatigue remission gap, requiring direct fatigue measurement and treatable-traits assessment
Who Might Benefit
Evidence fit by population:
- ▸Patients with inflammatory rheumatic diseases (RA, SLE, Sjögren's disease), including a 253-patient RA cohort and an international survey of 1,155 people with SjD.
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Narrative review, not a systematic review or meta-analysis, so selection bias possible
- ▸No central or metabolic biomarker for fatigue is ready for routine use
- ▸Evidence for immune-targeted therapies on fatigue is variable and generally small-to-moderate
Frequently Asked Questions
Why does fatigue persist even when inflammation is controlled in rheumatic diseases?▼
Fatigue is more strongly associated with pain, sleep disturbance, mood symptoms, central pain sensitivity, and deconditioning than with conventional inflammatory markers, leading to a 'fatigue remission gap'.
What is the 'fatigue remission gap'?▼
It is the mismatch between inflammatory remission and continuing fatigue, a practical signal that should prompt direct fatigue measurement and a treatable-traits assessment rather than automatic escalation of immunosuppression.
What treatments are supported for fatigue in rheumatic diseases?▼
Personalized exercise, rehabilitation, cognitive-behavioural or self-management interventions, and treatment of sleep disorders have supportive clinical evidence, whereas immune-targeted therapies produce variable, generally small-to-moderate improvements.
How common is fatigue in rheumatic diseases?▼
In a 2026 RA cohort of 253 patients, 80% reported fatigue and 10% had severe fatigue. In an international survey of 1,155 people with SjD, physical fatigue was among the most frequent symptoms, with mean work and activity impairment of 46.6% and 48.4%.
References
- 1.Gwóźdź-Broczkowska A. “Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework..” Rheumatology international, 2026. PMID: 42565853 DOI: 10.1007/s00296-026-06266-2